PD-1

[Nature Communications] Researchers described a human CD137xPD-L1 bispecific antibody, MCLA-145, identified through functional screening of agonist- and immune checkpoint inhibitor arm combinations.

[Nature] Scientists identified mutation-associated neoantigens (MANA)-specific T cell clones using the MANA functional expansion of specific T cells assay3 in neoadjuvant anti-PD-1-treated non-small cell lung cancers.

[Proceedings of the National Academy of Sciences of the United States of America] Leveraging the use of mass cytometry combined with multiplex major histocompatibility complex class I tetramer staining, researchers screened and identified tumor neoantigen–specific CD8+ T cells in the Lewis Lung carcinoma tumor model.

[Biochimica et Biophysica Acta-Reviews On Cancer] Investigators review the current progress targeting different immune checkpoints in several-lines treatment for TNBC, including programmed death-1/programmed death ligand-1 inhibitors, cytotoxic T-lymphocyte associated antigen-4 inhibitor, and other novel immunotherapeutic approaches.

[Stroke] Lymphocytes from Nur77GFP transgenic mice express a fluorescent protein upon activation via the TCR, allowing the differentiation of activation mode in a natural repertoire of immune cells and antigens.

[Science] Given the well-established role of CD4 T cells in sustaining germinal centers (GCs) and the emerging role of Foxp3 in suppressing this reaction, scientists sought to determine whether expression of Foxp3 by GC-resident T cells could also play a role in GC longevity.